Spotlight on Beyfortus

This 1-hour live panel discussion includes a scientific presentation followed by an interactive Q&A session with the opportunity to submit questions live.

August 16th

7:00 p.m. ET and 7:00 p.m. PT

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

• Neonates and infants born during or entering their first RSV season.
• Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.